VASO's first-quarter 2026 revenues dip after its healthcare IT divestiture, but losses narrow and deferred revenue kept climbing.
VASO posts steady fourth-quarter 2025 revenues but weaker earnings as higher costs and impairment charges weigh, though core segments and margins show resilience.
Vaso Corporation (OTCMKTS:VASO - Get Free Report) passed above its two hundred day moving average during trading on Thursday. The stock has a two hundred day moving average of $0.15 and traded as high as $0.17. Vaso shares last traded at $0.17, with a volume of 54,231 shares trading hands. Vaso Stock Performance The
| Consumer Finance Industry | Financials Sector | Jun Ma CEO | OTC PINK Exchange | 92233F102 CUSIP |
| US Country | 282 Employees | - Last Dividend | 16 Dec 1991 Last Split | 24 Oct 1988 IPO Date |
Vaso Corporation, initially known as Vasomedical, Inc. before rebranding in November 2016, is a multifaceted company deeply embedded in the healthcare sector. This conglomerate has a diverse operational footprint spanning the United States and various international markets, focusing on healthcare equipment and information technology industries. Established in 1987 and based in Plainview, New York, Vaso Corporation orchestrates its business operations through three main segments: IT, Professional Sales Service, and Equipment. These segments collaboratively contribute to the company’s dedication to enhancing healthcare delivery through innovative technology and services.
Vaso Corporation's diverse array of products and services is categorized into three primary segments, each serving a unique role within the healthcare industry: